AddLife delivered 8% sales growth and a 21% EBITA increase in Q2 2024, with both Labtech and Medtech segments performing strongly. Improved cash flow, reduced debt, and the Bonsai Lab acquisition support a positive outlook for the rest of the year.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.